De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Inventiva Beheer

Beheer criteriumcontroles 2/4

De CEO Inventiva's is Frederic Cren, benoemd in Jan2011, heeft een ambtstermijn van 13.75 jaar. De totale jaarlijkse vergoeding van { bedraagt € 1.00M, bestaande uit 30.4% salaris en 69.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 10.72% van de aandelen van het bedrijf, ter waarde € 9.43M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 8.1 jaar en 7.7 jaar.

Belangrijke informatie

Frederic Cren

Algemeen directeur

€1.0m

Totale compensatie

Percentage CEO-salaris	30.4%
Dienstverband CEO	13.8yrs
Eigendom CEO	10.7%
Management gemiddelde ambtstermijn	8.1yrs
Gemiddelde ambtstermijn bestuur	7.7yrs

Recente managementupdates

Shareholders May Not Be So Generous With Inventiva S.A.'s (EPA:IVA) CEO Compensation And Here's Why

Jun 14

Recent updates

Inventiva S.A. (EPA:IVA) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Sep 27

More Unpleasant Surprises Could Be In Store For Inventiva S.A.'s (EPA:IVA) Shares After Tumbling 28%

Jun 18

Shareholders May Not Be So Generous With Inventiva S.A.'s (EPA:IVA) CEO Compensation And Here's Why

Jun 14

Optimistic Investors Push Inventiva S.A. (EPA:IVA) Shares Up 27% But Growth Is Lacking

Mar 19

Here's What Inventiva S.A.'s (EPA:IVA) Shareholder Ownership Structure Looks Like

Jan 29

Is Inventiva's (EPA:IVA) 223% Share Price Increase Well Justified?

Dec 07

Analyse CEO-vergoeding

Hoe is Frederic Cren's beloning veranderd ten opzichte van Inventiva's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-€104m
Mar 31 2024	n/a	n/a	-€107m
Dec 31 2023	€1m	€305k	-€110m
Sep 30 2023	n/a	n/a	-€95m
Jun 30 2023	n/a	n/a	-€80m
Mar 31 2023	n/a	n/a	-€67m
Dec 31 2022	€878k	€300k	-€54m
Sep 30 2022	n/a	n/a	-€55m
Jun 30 2022	n/a	n/a	-€56m
Mar 31 2022	n/a	n/a	-€56m
Dec 31 2021	€929k	€299k	-€50m
Sep 30 2021	n/a	n/a	-€45m
Jun 30 2021	n/a	n/a	-€41m
Mar 31 2021	n/a	n/a	-€36m
Dec 31 2020	€388k	€267k	-€34m
Sep 30 2020	n/a	n/a	-€29m
Jun 30 2020	n/a	n/a	-€25m
Mar 31 2020	n/a	n/a	-€27m
Dec 31 2019	€374k	€243k	-€30m
Sep 30 2019	n/a	n/a	-€34m
Jun 30 2019	n/a	n/a	-€37m
Mar 31 2019	n/a	n/a	-€35m
Dec 31 2018	€376k	€243k	-€33m
Sep 30 2018	n/a	n/a	-€29m
Jun 30 2018	n/a	n/a	-€25m
Mar 31 2018	n/a	n/a	-€22m
Dec 31 2017	€372k	€243k	-€19m

Compensatie versus markt: De totale vergoeding ($USD 1.11M ) Frederic } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de French markt ($USD 354.64K ).

Compensatie versus inkomsten: De vergoeding van Frederic is gestegen terwijl het bedrijf verliesgevend is.

CEO

Frederic Cren (58 yo)

13.8yrs

Tenure

€1,003,699

Compensatie

Mr. Frederic Cren has been Chief Executive Officer of Inventiva S.A. since co-founding Inventiva S.A. in 2011. Mr. Cren has been Chairman at Inventiva S.A. since May 31, 2016. He served as President of Inv...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Frederic Cren	Co-Founder	13.8yrs	€1.00m	10.72% € 9.4m
Pierre Broqua	Co-Founder	13.8yrs	€938.43k	7.41% € 6.5m
Jean Volatier	Deputy GM & CFO	12.2yrs	geen gegevens	0.29% € 251.7k
Alice Roudot-Ketelers	Chief Operating Officer	1.7yrs	geen gegevens	0.029% € 25.2k
Eric Duranson	General Counsel	3.3yrs	geen gegevens	0.029% € 25.2k
Nathalie Harroy	Head of Human Resources	12.8yrs	geen gegevens	0.13% € 110.4k
Kristina Meyer	Executive VP and Business Development & Alliance Management	no data	geen gegevens	geen gegevens
Michael Cooreman	Chief Medical Officer	4yrs	geen gegevens	0.029% € 25.2k
Pascaline Clerc	Executive Vice President of Strategy & Corporate Affairs	less than a year	geen gegevens	0.014% € 12.6k

8.1yrs

Gemiddelde duur

57.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van IVA is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Frederic Cren	Co-Founder	8.4yrs	€1.00m	10.72% € 9.4m
Pierre Broqua	Co-Founder	8.4yrs	€938.43k	7.41% € 6.5m
Chris Buyse	Independent Director	7.7yrs	€61.20k	0% € 0
Annick Schwebig	Independent Director	7.7yrs	€61.20k	0.0059% € 5.2k
Jean-Louis Junien	Chairman of Scientific Advisory Board	no data	€16.00k	geen gegevens
Xiaoqin Lu	Independent Director	6.4yrs	€43.20k	geen gegevens
Heinz Maeusli	Independent Director	5.4yrs	€49.20k	geen gegevens
Sven Francque	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Manal Abdelmalek	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Kenneth Cusi	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Glen Clack	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Gérard Zalcman	Scientific Advisory Board Member	no data	geen gegevens	geen gegevens

7.7yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van IVA wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.7 jaar).

Inventiva Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Shareholders May Not Be So Generous With Inventiva S.A.'s (EPA:IVA) CEO Compensation And Here's Why

Inventiva S.A., Annual General Meeting, Jan 25, 2023

Inventiva Announces Lucy Lu as the Director of its Board of Directors

Insufficient new directors

Insufficient new directors

Inventiva S.A., Annual General Meeting, May 19, 2022

Recent updates

Inventiva S.A. (EPA:IVA) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

First half 2024 earnings released: €0.94 loss per share (vs €1.32 loss in 1H 2023)

Price target decreased by 20% to €10.64

Consensus revenue estimates increase by 113%

More Unpleasant Surprises Could Be In Store For Inventiva S.A.'s (EPA:IVA) Shares After Tumbling 28%

Shareholders May Not Be So Generous With Inventiva S.A.'s (EPA:IVA) CEO Compensation And Here's Why

Consensus revenue estimates decrease by 67%

Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor

Consensus revenue estimates decrease by 21%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Optimistic Investors Push Inventiva S.A. (EPA:IVA) Shares Up 27% But Growth Is Lacking

New minor risk - Share price stability

Inventiva S.A. Provides Update on its Clinical Trial NATiV3

Some Confidence Is Lacking In Inventiva S.A.'s (EPA:IVA) P/S

Consensus EPS estimates fall by 13%

Forecast to breakeven in 2026

Inventiva S.A. to Report First Half, 2024 Results on Sep 25, 2024

Price target decreased by 14% to €15.35

Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development Program

Price target decreased by 7.4% to €16.50

New major risk - Negative shareholders equity

First half 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 216%

New major risk - Negative shareholders equity

Consensus revenue estimates decrease by 78%

New major risk - Financial position

New minor risk - Shareholder dilution

Consensus revenue estimates decrease by 19%

Inventiva S.A. to Report Fiscal Year 2023 Results on Mar 27, 2024

Consensus revenue estimates increase by 573%

Inventiva S.A. to Report Nine Months, 2023 Results on Sep 28, 2023

New major risk - Revenue and earnings growth

Price target increased by 15% to €18.76

Inventiva Announces Positive Topline Results from the Investigator-Initiated Phase Ii Clinical Trial Evaluating Lanifibranor in Patients with T2d and NAFLD

Analyst Forecasts Just Became More Bearish On Inventiva S.A. (EPA:IVA)

Consensus revenue estimates decrease by 15%

Pinning Down Inventiva S.A.'s (EPA:IVA) P/S Is Difficult Right Now

Consensus revenue estimates decrease by 37%

Revenue Downgrade: Here's What Analysts Forecast For Inventiva S.A. (EPA:IVA)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2025

Inventiva S.A. to Report Fiscal Year 2022 Results on Mar 29, 2023

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A., Annual General Meeting, Jan 25, 2023

Inventiva Announces Lucy Lu as the Director of its Board of Directors

Insufficient new directors

Inventiva Provides Update on Development of cedirogant by AbbVie

Consensus revenue estimates increase by 10%

Consensus revenue estimates increase by 352%

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Inventiva S.A. to Report First Half, 2022 Results on Sep 21, 2022

Inventiva Announces the Screening of the First Patient in LEGEND , Phase IIa Combination Trial with Lanifibranor and Empagliflozin in Patients with NASH and T2D

Despite Lacking Profits Inventiva (EPA:IVA) Seems To Be On Top Of Its Debt

Price target decreased to €19.96

Inventiva Announces Three Scientific Presentations At the EASL International Liver Congress™ 2022

Insufficient new directors

Consensus forecasts updated

No longer forecast to breakeven

Inventiva S.A., Annual General Meeting, May 19, 2022

Inventiva S.A. Announces IND Application for the Phase Ii Combination Trial with Lanifibranor and Empagliflozin in Patients with Nash

Forecast to breakeven in 2024

Inventiva S.A. to Report Fiscal Year 2021 Results on Mar 07, 2022

Inventiva receives a €4 Million Milestone Payment from AbbVie for Cedirogant Phase IIb Initiation

Forecast to breakeven in 2024

Inventiva Announces Positive Results of Clinical Thorough QT Study Conducted with Lanifibranor

Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $30.00001 million.

Second quarter 2021 earnings released: €0.37 loss per share (vs €0.29 loss in 2Q 2020)

Inventiva Announces the Initiation of Its Pivotal Phase III Clinical trial Evaluating Lanifibranor in NASH